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Abstract: Interleukin-1 beta (IL-1β) is induced by inflammatory signals in a broad number of
immune cell types. IL-1β (and IL-18) are the only cytokines which are processed by caspase-1
after inflammasome-mediated activation. This review aims to summarize current knowledge
about parameters of regulation of IL-1β expression and its multi-facetted role in pathophysiological
conditions. IL-1 signaling activates innate immune cells including antigen presenting cells, and drives
polarization of CD4+ T cells towards T helper type (Th) 1 and Th17 cells. Therefore, IL-1β has
been attributed a largely beneficial role in resolving acute inflammations, and by initiating
adaptive anti-tumor responses. However, IL-1β generated in the course of chronic inflammation
supports tumor development. Furthermore, IL-1β generated within the tumor microenvironment
predominantly by tumor-infiltrating macrophages promotes tumor growth and metastasis via
different mechanisms. These include the expression of IL-1 targets which promote neoangiogenesis
and of soluble mediators in cancer-associated fibroblasts that evoke antiapoptotic signaling in tumor
cells. Moreover, IL-1 promotes the propagation of myeloid-derived suppressor cells. Using genetic
mouse models as well as agents for pharmacological inhibition of IL-1 signaling therapeutically
applied for treatment of IL-1 associated autoimmune diseases indicate that IL-1β is a driver of tumor
induction and development.
Keywords: interleukin-1β; promoter; inflammasome; tumor; tumor-associated macrophage;
myeloid-derived suppressor cell
1. Introduction
Many aspects of the multi-facetted biological roles of Interleukin-1 alpha (IL-1α), and its functional
homolog, but structurally different relative IL-1β were elucidated by the Dinarello lab [1]. IL-1α and
IL-1β constitute the founding members of the IL-1 family which by now comprises eleven members [2].
Of note, all IL-1 family members are expressed as zymogens and most require proteasomal cleavage
to yield biologically active mature forms. Of these, pro-IL-1β and pro-IL-18 are unique as they are
cleaved by activated inflammasomes [3]. These multi-protein complexes are assembled in response to
exogenous and endogenous danger signals and induce activation of caspases that generate bioactive
IL-1β and IL-18. IL-1β is generated and released by numerous distinct immune and non-immune
cell types rapidly in response to inflammatory signals [1]. In contrast, IL-1α is rather constitutively
expressed in many non-immune cell types, but mainly remains in the cytosol or bound to the cell
surface released in case of cell necrosis [4].
IL-1β acts as an amplifier of immune reactions [1]. In agreement, IL-1 exerts potent pyrogenic
activity. For quite a long time, IL-1 has been widely acknowledged as required for efficient
initiation of innate and shaping of adaptive immune responses to resolve acute inflammations [2].
However, the view of IL-1β as a beneficial immune regulator has been challenged by the finding that
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gain-of-function mutations in components of inflammasomes result in excessive IL-1β production that
contribute to autoimmune [5] and cause autoinflammatory [1] diseases. In addition, in the case of
chronic inflammation, sustained IL-1β may promote both tumor induction and later on also tumor
propagation by different mechanisms [2]. Interestingly, we and others have shown that a number of
anti-tumor therapeutics induces IL-1β production [6].
This review article aims to summarize our current knowledge on the different layers of
regulation of IL-1β expression, and the multi-facetted biological roles of this important cytokine
under pathophysiological conditions with a focus on tumor development.
2. Production of IL-1β Requires Two Distinct Signals
The different signaling pathways and transcription factors which elevate IL-1β gene expression in
response to proinflammatory mediators, including IL-1β itself, have been thoroughly assessed. Besides
transcriptional regulation, the half-life of generated IL-1β mRNA is regulated on posttranscriptional
level by RNA-binding proteins. Derived pro-IL-1β protein requires proteolytic cleavage to acquire
functional activity. This step is mainly facilitated by active caspase-1 as the effector component of
stimulation-induced multi-protein inflammasomes. Altogether, these different layers of regulation
allow to fine tune IL-1β production under different pathophysiological conditions as early recognized
in human monocytic cells [7,8].
2.1. Gene Expression
The gene structure, expressional regulation, and function of IL-1β are evolutionarily well
conserved [9]. In most studies the characteristics of regulatory elements of the human IL-1β gene
promoter have been studied in human monocytic cells.
2.1.1. Transcriptional Gene Regulation
The TATA box containing the core promoter region of the IL-1β gene [10] harbors two bindings
sites each for the myeloid-specific Ets-domain containing transcription factor (TF) PU.1 [11] and
the leucine zipper containing TF CCAAT/enhancer binding protein (C/EBP-)β [12] (Figure 1).
For keratinocytes, a specificity protein-1 (SP-1) binding site within the core promoter was identified
as essential for steady state IL-1β mRNA expression [13]. Inflammatory stimuli such as toll-like
receptor (TLR) ligands, tumor necrosis factor-α (TNF-α) or IL-1β itself [14] converge on activation
of the signaling adaptor myeloid differentiation primary response 88 (MyD88) [15] which, besides
other signaling pathways, is known to stimulate C/EBP [16]. In agreement, C/EBP-β was found to
confer upregulation of IL-1β gene expression in response to the TLR4 ligand lipopolysaccharide (LPS)
derived from gram-negative bacteria [17,18]. Of note, synergistic interaction of C/EBP-β with PU.1
did not require DNA binding of the former, but resulted from protein-tethered transactivation [12].
Furthermore, the endogenous danger molecule high mobility group box 1 protein (HMGB1) which
is released by necrotic cells [19] was reported to enhance IL-1β gene expression via interaction with
PU.1 as well [20]. Immediately upstream of the transcription start site, the IL-1β core promoter region
also contains a functional binding site for the zinc finger-containing transcriptional repressor KLF4,
which is induced by proinflammatory stimuli as well, and thereby limits IL-1β gene expression [21].
Upstream of the core promoter, a functional nuclear factor kappa-light-chain-enhancer of activated
B-cells (NF-κB) binding site was reported to contribute to elevated IL-1β gene expression after
stimulation [22]. MyD88 activation resulted in both direct MyD88/IκB kinase (IKK)-dependent
degradation of IκB as a prerequisite for the release of NF-κB dimers and stimulation of mitogen
activated protein kinase kinase (MKK) activity [23]. MyD88 activation was reported to stimulate
cold-inducible RNA binding protein (CIRBP) which in turn down-regulated IκB expression and hence
promoted IL-1β expression [24]. Lebedeva and Singh [25] identified a palindromic AT-rich sequence
stretch located closely downstream of the NF-κB site to constitutively inhibit IL-1β promoter activity,
but could not identify the transcriptional repressor involved. An inducible glucocorticoid response
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element (GRE) located upstream of the NF-κB site inhibited IL-1β gene expression in response to
dexamethasone which activates the TF glucocorticoid repressor (GR) [26]. As another layer of negative
IL-1β gene regulation, the activated GR was reported to directly inhibit LPS-induced NF-κB and
activator protein-1 (AP-1) on protein level [27]. In addition, GR-induced MKP-1 was shown to repress
LPS-induced IL-1β induction via MKK repression by direct protein-protein interaction [28].
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conditions in antigen presenting cells (APC) [30]. In line, the aforementioned HIF1 sites also 
contributed to IL-1β upregulation under according circumstances [29]. Furthermore, stimulation of 
myeloid cells with LPS-induced interferon response factors (IRF-)4 and IRF-8, and resulted in 
activation of PU.1 via protein kinase CK2 mediated phosphorylation [31]. IRF4/8 and PU.1 engaged 
a composite binding site and synergized to mediate IL-1β gene transcription [32]. Gray and 
coworkers [33] identified a cAMP-responsive element (CRE) adjacent to the composite PU.1/IRF 
binding site. This CRE site conferred stimulation of IL-1β gene expression in response to cAMP-
elevating agents such as prostaglandin E2 in monocytes. In contrast, cAMP induction prevented LPS-
mediated upregulation of IL-1β mRNA in astrocytes [34]. 
Different components of the extracellular matrix such as fibronectin, type I collagen, and laminin 
engage integrin receptors known to result in activation of protein kinase C (PKC) [35]. Activated PKC 
in turn stimulated AP-1 and thereby IL-1β gene expression [36]. In addition, PKC is associated with 
the MyD88 signaling cascade [37]. Thus far, no specific AP-1 binding site has been identified within 
the IL-1β gene promoter. Therefore, it remains possible that the CRE site identified by Gray and 
coworkers [33] may be engaged by TF of the AP-1 family as well. GATA-2 as a member of the 
“GATA” sequence binding TF family has also been implicated in MyD88/MKK transmitted 
upregulation of IL-1β mRNA expression [38]. However, none of the several potential GATA binding 
sites have been delineated as functionally active. 
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Three closely spaced putative hypoxia-induced factor 1 (HIF1) binding sites were demonstrated
to confer hypoxia-induced IL-1β upregulation [29]. Of note, HIF1 is also induced under stimulatory
conditions in antigen presenting cells (APC) [30]. In line, the aforementioned HIF1 sites also contributed
to IL-1β upregulation under according circumstances [29]. Furthermore, stimulation of myeloid cells
with LPS-induced interferon response factors (IRF-)4 and IRF-8, and resulted in activation of PU.1 via
protein kinase CK2 mediated phosphorylation [31]. IRF4/8 and PU.1 engaged a composite binding
site and synergized to mediate IL-1β gene transcription [32]. Gray and coworkers [33] identified
a cAMP-responsive element (CRE) adjacent to the composite PU.1/IRF binding site. This CRE
site conferred stimulation of IL-1β gene expression in response to cAMP-elevating agents such as
prostaglandin E2 in monocytes. In contrast, cAMP induction prevented LPS-mediated upregulation of
IL-1β mRNA in astrocytes [34].
Different components of the extracellular matrix such as fibronectin, type I collagen, and laminin
engage integrin receptors known to result in activation of protein kinase C (PKC) [35]. Activated PKC
in turn stimulated AP-1 and thereby IL-1β gene expression [36]. In addition, PKC is associated with
the MyD88 signaling cascade [37]. Thus far, no specific AP-1 binding site has been identified within
the IL-1β gene promoter. Therefore, it remains possible that the CRE site identified by Gray and
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coworkers [33] may be engaged by TF of the AP-1 family as well. GATA-2 as a member of the “GATA”
sequence binding TF family has also been implicated in MyD88/MKK transmitted upregulation of
IL-1β mRNA expression [38]. However, none of the several potential GATA binding sites have been
delineated as functionally active.
The overall accessibility of IL-1β gene promoter was found to be inhibited by DNA methylation in
promyeloid cells while differentiated monocytes were devoid of methylated CpG motifs [39]. In models
of LPS tolerance, phosphorylation of histone H3 serine around the IL-1β gene promoter was reduced
and binding of the heterochromatin protein-1 (HP-1) was elevated, which correlated with repressed
IL-1β gene expression [40].
In a systemic sequencing approach, Chen and coworkers [41] identified a number of single
nucleotide polymorphisms (SNP) within the IL-1β gene locus, and performed functional assays
identifying four SNP to affect overall promoter activity of stimulated monocytic cells. A mutation
within the TATA box (SNP B15 [-31]: T ≥ C) diminished stimulation-induced promoter activity. At the
same time, this mutation created a functionally active binding site for the TF Yin Yang 1 (YY1) [42],
known to stimulate or silence gene expression [43]. SNP B14 (−511: C ≥ T) exerted a pronounced
stimulatory effect on transcriptional activity of stimulated monocytic cells, whereas SNP B10 (−1464)
and SNP B4 (−3737) moderately decreased overall promoter activity [41].
In a growing number of studies, the prevalence of those alleles within the IL-1β core (SNP B15
TT>CC) and proximal (SNP B14 TT>CC) promoter that conferred higher IL-1β gene expression was
found to be associated with an enhanced susceptibility or aggravated course of disease. This included
infectious diseases such as tuberculosis [44], neurodegenerative diseases such as Alzheimer’s
disease [45], autoimmune and autoinflammatory diseases such as psoriasis [46] and diabetes type 2 [47],
and the occurrence of tumors such as prostate cancer [48].
2.1.2. Posttranscriptional Gene Regulation
Expression of human IL-1β has been demonstrated to be regulated not only on transcriptional
level, but also by modulation of the IL-1β mRNA half-life. In this regard, Marucha and coworkers [49]
demonstrated that treatment of human neutrophils with proinflammatory cytokines (IL-1β, TNF-α)
transiently elevated both de novo IL-1β gene transcription as well as the half-life of IL-1β
mRNA. On the contrary, IL-4 was identified as a negative regulator of IL-1β mRNA stability in
LPS-stimulated monocytes [50]. In subsequent studies, the 3’-untranslated region of IL-1β mRNA
was demonstrated to contain several functional AU-rich elements (ARE) which are engaged by a
class of RNA-binding proteins [51]. Sirenko and coworkers [52] detected p38 mitogen-activated
protein kinase (MAPK)-dependently activated ARE RNA-binding protein 1 (AUF1) to bind two of
these ARE upon surface detachment of monocytes. AUF1 binding attenuated IL-1β mRNA stability.
Similarly, we demonstrated that dendritic cells (DC) derived from mice deficient for the ARE-binding
factor tristetraprolin were characterized by stronger upregulation of IL-1β mRNA in response to LPS
treatment as compared with wild type DC due to a prolonged mRNA half-life [53].
2.2. Processing of Pro-IL-1β
The biogenesis of most IL-1 family members differs from other cytokines insofar as most IL-1
interleukins are generated as biologically inactive zymogen forms which are proteolytically cleaved [54].
In the case of IL-1β (and IL-18), N-terminal processing is facilitated in myeloid cell types by caspases
which often serve as the effector component of inflammasomes. However, (partial) activation is also
conferred by other proteases released by activated neutrophils and mast cells [55].
2.2.1. Caspases
Cytoplasmic danger receptors that belong to the NLR protein family such as nucleotide-binding
oligomerization domain-like receptor family leucine-rich repeat protein (NLRP) 1, NLRP3, and NLR
family caspase recruitment domain containing 4 (NLRC4), or other types of danger receptors such
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as AIM2 (absent In melanoma 2), IFI-16 (interferon gamma inducible protein 16), RIG-1 (retinoic
acid inducible gene-1), and MEFV (mediterranean fever) induce the formation of multi-protein
inflammasomes in response to engagement by according ligands [3]. For this, binding of
receptor-specific danger signals such as LPS, which specifically activates NLRP3, or flagellin, which is
recognized by NLRC4, initiates inflammasome formation via inclusion of the adaptor protein
ASC (activating signal cointegrator). These canonical inflammsomes recruit caspase-1 which in a
proximity-dependent manner becomes autoproteolytically self-activated [56]. Dimeric active caspase-1
then mediates cleavage of pro-IL-1β and pro-IL-18.
By now, most studies have assessed the properties of NLRP3-based inflammasomes. In response
to inflammation-induced MyD88 signaling, NLRP3 expression is upregulated as a prerequisite for
formation of NLRP3 inflammasomes [57]. Of note, NLRP3 expression is negatively regulated on
posttranscriptional level by the myeloid-specific micro-RNA (miR-)223 [58]. miR-223 has been
attributed potent anti-inflammatory function in macrophages [59] as a consequence of inhibition
of TF belonging to the NF-κB, C/EBP and STAT (signal transducer and activator of transcription)
families [60].
On protein level, NLRP3 activity is mediated by deubiquitination as induced by TLR ligands [61].
NLRP3 oligomerization and activation requires interaction with NEK (NIMA-related kinase) after
NLRP3-stimulation associated potassium efflux [62]. In a positive feedback loop, NLRP3 contributes
to activation of NF-κB after microbial infection and application of particulate adjuvants [63]. However,
sustained NLRP3 inflammasome activity is inhibited both by long-term LPS priming as well as
inflammation-induced type I interferon (IFN) [64]. In both cases, nitric oxide synthase type 2 is
induced which generates nitric oxide resulting in nitrosylation of NLRP3. Moreover, A20, which confers
both ubiquitin ligase and deubiquitinase activities, was identified as a NLRP3-specific inhibitor [65].
Prostaglandin-induced cAMP serves as an endogenous modifier of NLRP3 inflammasome activation
as well. Prostaglandin E receptor 4 (EP4) signaling inhibited inflammasome activity in a protein kinase
A (PKA) and exchange protein directly activated by cAMP (EPAC) independent manner [66]. On the
contrary, signaling via EP3 elevated LPS-induced inflammasome activity [67].
Non-canonical inflammasomes lack a specific endogenous danger receptor, and are comprised of
caspase-4 and -5 in human [68] or caspase-11 in mouse [69]. These inflammasomes are directly activated
by intracellular LPS to confer pro-IL-1β and-IL-18 processing. In both cases, inflammasome activation
may also result in lytic cell death, termed pyroptosis, due to cleavage-dependent activation of the pore
forming protein gasdermin D [70]. More recently, an alternative NLRP3-associated inflammasome
pathway has been described in human monocytes which is also induced by LPS or the endogenous
TLR4 ligand oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) [71].
In contrast to canonical inflammasomes, this pathway does not result in pyroptosis.
Caspase-8 is activated by CD95 and TNF receptor 1 signaling, and mediates cell apoptosis [72].
However, in a number of studies, caspase-8 was shown to replace caspase-1 as the effector molecule of
NLR (NLRP3, NLRC4) and non-NLR (AIM2) inflammasomes [73,74]. In addition, CD95 engagement [75]
and LPS-induced formation of Fas-associated via death domain (FADD)/caspase-8 containing
ripoptosomes [76] resulted in processing of pro-IL-1β in an inflammasome-independent manner.
In a growing number of studies, gain-of-function mutations of inflammasome initiating
cytoplasmic danger receptor proteins were demonstrated to mediate an increase in overall IL-1β
levels [5]. Gain-of-function mutations of NLRP3 [77] and NLRC4 [78] have been associated with
autoimmune diseases which overlap in their symptoms, termed cryopyrin-associated periodic
syndromes (CAPS). Interestingly, in CAPS patients with mutated NLRP3, catalytically active
extracellular NLRP3 inflammasomes were detected [79]. These extracellular complexes were also
internalized by other macrophages, spreading excessive IL-1β maturation.
Besides gain-of-function mutations of inflammsome proteins, a functional NLRP1 promoter
polymorphism resulting in elevated gene expression was associated with increased susceptibility
towards rheumatoid arthritis [80] and generalized vitiligo [81].
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2.2.2. Other Proteases
Neutrophils [82] and mast cells [83] store many different proteases in their granules that,
upon release, exert divergent anti-pathogenic effects. Of these, elastase and closely related cathepsin G
as well as chymase were shown to cleave pro-IL-1β at the same site, some residues upstream of the
caspase cleavage site [55]. Extracellular maturation of IL-1β may be important in case of myeloid cells
that shed pro-IL-1β containing membrane microvesicles [84] that are lysed by ATP [85]. In addition,
the membrane integrity of pro-IL-1β producing leukocytes is disturbed by prolonged exposure to
antimicrobial peptides [86] and as a consequence of inflammasome activation itself (pyroptosis)
resulting in release of pro-IL-1β. Besides extracellular cleavage of pro-IL-1β, it remains possible that
cathepsin G endogenously generated by leukocytes [87,88] may promotes cleavage of pro-IL-1β too.
3. IL-1β Signaling
3.1. The IL-1 Receptor
The Interleukin-1 receptor (IL-1R) family comprises 10 members which share a highly similar
structure. They consist of extracellular immunoglobulin domains as well as a cytoplasmic Toll/IL-1
receptor (TIR) domain, except for IL-1R2 [89]. Of these receptors, only IL-1R1 and IL-1R2 are
able to bind IL-1α and IL-1β as well as the receptor antagonist IL-1Ra [90]. Since IL-1R2 lacks
the TIR domain, it cannot induce signaling upon substrate binding [91,92]. IL-1R2 constitutes a
“decoy receptor” due to its capability to bind IL-1 without initiating IL-1 signaling [93]. IL-1R1 and
IL-1R2 are expressed by a plethora of cells including immune cells and others [90]. Especially T
cells, polymorphonuclear leukocytes, DC, monocytes, macrophages, and B cells express IL-1R1 and
IL-1R2 [90]. Furthermore, IL-1R1 is expressed by most epithelial cells [90]. In mice, IL-1R2 is mainly
apparent in neutrophils [94,95]. IL-1R3, the accessory chain of the IL-1R members, is expressed by all
IL-1 responsive cell types [90].
3.2. IL-1β Signaling Cascade
Binding of the agonists IL-1α or IL-1β to IL-1R1 results in conformational changes of the receptor
and in the formation of IL-1R1/IL-1R3 complexes (Figure 2) [96–98]. These conformational changes
cause the TIR domain of IL-1R3 to get to close proximity to the TIR domain of IL-1R1 which induces
IL-1 signaling [99]. Alternatively, IL-1 may engage IL-1R, and this complex subsequently engages
IL-1R3, without inducing IL-1 signaling [90,100]. In addition, the receptor antagonist IL-1Ra can bind
to IL-1R1, and thereby prevents the formation of the IL-1R complex [101].
Upon formation of the IL-1R complex, the two intracellular TIR domains of IL-1R1 and IL-1R3
recruit the TIR domain-containing adaptor protein MyD88 [102–105]. The attracted MyD88 proteins
constitue oligomers which form a death domain (DD) important for subsequent signaling [106].
The DD of MyD88 recruits proteins of the IL-1R-associated kinase (IRAK) family. First, IRAK-4 binds to
MyD88 followed by IRAK-1 and-2 [107,108], Toll-interacting protein (Tollip) [109] as well as Pellino-1
(PELI-1) and-2. PELI-1 and-2 are E3-ubiquitin ligases [110]. Non-phosphorylated IRAK-1 bound to
Tollip is inactive [111]. When IRAK-1 binds to the IL-1R complex, it is phosphorylated and thereby
activated through IRAK-4 activity and dissociates from Tollip and from the IL-1R complex [109,112].
IRAK-1 becomes hyper-autophosphorylated due to its activation by IRAK-4. Then, TRAF6 (TNF
receptor-associated factor 6) is recruited to hyperphosphorylated IRAK-1 followed by the activation
of its E3 ubiquitin ligase activity [113]. At the same time, IRAK-4 phosphorylates and activates
PELI-1 and-2 [114,115]. TAK1 binding protein (TAB)2 and TAB3 are ubiquitinated by activated
PELI or TRAF6 and recruit the TGFβ1-activated kinase (TAK)1/TAB1 complex [116]. This event
results in a conformational change of the complex that leads to autophosphorylation and activation
of TAK1 [117,118]. TAK1 phosphorylates and activates downstream kinases such as the MKK or
IKK complex which regulate target gene expression [119]. IRAK-2 can replace IRAK-1, but it lacks
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the autophosphorylation activity of IRAK-1, and is therefore not targeted for fast degradation [120].
Thereby, IRAK-1 is a more stable signaling component of the IL-1 pathway [90].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 33 
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3.3. IL-1Ra and IL-1R2
IL-1Ra is structurally similar to IL-1α and IL-1β. Therefore, it is a competitor for binding to
IL-1R1 [121]. In contrast to IL-1α and IL-1β, IL-1Ra blocks the downstream IL-1 signaling pathway
by preventing the binding of IL-1R3 to IL-1 binding IL-1R1 [98]. Interestingly, IL-1Ra does not
bind to IL-1R2 [122]. Four isoforms of IL-1Ra are known, one secreted isoform and three intracellular
isoforms [121]. Only the secreted isoform has been characterized yet [122]. Bellehumeur and coworkers
showed that human endometrial cells respond to IL-1β by increasing the levels of IL-1R1 and IL-1Ra
by gene transcription, which IL-1R2 showed an enhanced mRNA stability [123].
A condition termed deficiency of interleukin-1 antagonist (DIRA) in humans proves the
importance of IL-1Ra for the regulation of IL-1β signaling. DIRA results in lethal sterile multi-organ
inflammation if not treated with recombinant IL-1Ra [90,124]. Furthermore, a variable number of
tandem repeats polymorphism in the IL-1Ra gene (IL-1RN) was shown to be associated with an
increased risk to develop cancer [59]. Furthermore, a study showed that the synonymous coding
variant rs315952 of IL-1RN is strongly correlated with improved survival after septic shock due to
increased plasma levels of IL-1RA [125].
IL-1R2 exists as a membrane-bound and as a soluble form. Both can bind both IL-1α and IL-1β,
with higher affinity to IL-1β, and inhibit the IL-1 signaling cascade by preventing both cytokines from
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binding to IL-1R1 [90,126,127]. The soluble form of IL-1R2 is either generated through proteolytic
cleavage of the extracellular region [94,128–131] or by alternative splicing [101,132,133]. Both IL-1Ra
and IL-1R2 regulate IL-1 signaling by different mechanisms, and thereby reduce IL-1-mediated
inflammation [9].
IL-1R2 was shown to play important roles in several diseases such as diabetes, atherosclerosis,
sepsis, Alzheimer’s disease, autoimmune inner ear disease (AIED), ulcerative colitis, and arthritis [134].
AIED patients do not express the full length and thereby functional IL-1R2 in their peripheral blood
cells which suggests a protective function of IL-1R2 in AIED [135]. A recent study by Mora-Buch
and coworkers showed that IL-1R2 production by epithelial cells was increased during remission of
ulcerative colitis [136]. These results were confirmed by the finding that IL-1R2 transcription was
reduced in patients that relapsed within 1 year compared to patients in remission. In addition, Shimizu
and coworkers identified IL-R2 as an important regulator of arthritis. IL-1R2 inhibits collagen-induced
arthritis by downregulation of the IL-1 signaling cascade in macrophages [95].
4. Role of IL-1 in Inflammation
IL-1 was early identified as an important hematopoietic factor that induced expression of
colony stimulating factors on progenitor cells as well as leukocytes and stroma cells [137]. In line,
administration of IL-1 to lethally irradiated mice resulted in recovery of the myeloid compartment [138].
IL-1 has been strongly implicated in the inflammatory response of immune cells due to its
pronounced IKK [139] and MEK [140] stimulatory effects including upregulation of MyD88 [141].
In this regard, IL-1 constitutes a potent stimulator of APC as initially described by Koide and coworkers
using recombinant IL-1α for murine splenic DC [142], and confirmed by Heufler and coworkers
identifying IL-1β as the relevant factor for the maturation of Langerhans cells [143] that constitute the
epidermal DC population. Furthermore, IL-1β was shown to promote the differentiation of monocytes
to conventional DC [139] and to M1-like macrophages [144]. In addition, IL-1 was early demonstrated
to support the proliferation of activated B cells and their differentiation to plasma cells [145]. IL-1 in
combination with IL-2 promoted the expansion of natural killer (NK) cells as well as of CD4+ CD8+ T
cells [146]. Moreover, IL-1β generated by activated APC induced type 1 immune responses. This was
reflected by elevating frequencies of IFN-γ producing cytotoxic T lymphocytes (CTL) [147] and the
polarization of αβ CD4+ T cells towards T helper cell type 1 (Th1) [148]. However, IL-1 was also
reported to induce IL-4 receptor expression on CD4+ T cells [149] which is necessary for maintenance of
Th2 cells. In combination with IL-6 [150] and IL-23 [151], IL-1β favored the differentiation of αβ CD4+
T cells towards Th17. Of note, IL-1β was described to counter-act TGF-β induced Foxp3 expression in
CD4+ T cells, thereby inhibiting the differentiation of regulatory T cells (Treg) [152]. Moreover, IL-1β
induced alternative splicing of Foxp3 in Treg resulting in a functional switch towards Th17 [153].
IL-1β not only promoted Th17 polarization via IL1R signaling, but also supported APC-induced
Th17 production by CD4+ memory T cells. In this regard, human DC were reported to upregulate
both surface-bound and soluble CD14 which interacted with T cell surface receptors promoting IL-17
production [154]. In the case of memory Th17 cells, IL-1β inhibited restimulation-induced IL-10
production [155]. Similar to αβ CD4+ T cells, IL-1 with IL-23 also induced IL-17 production by γδ
CD4+ T cells [156].
IL-1 induced in the course of acute inflammation promoted the upregulation of adhesion receptors
on immune and endothelia cells as a prerequisite for infiltration of leukocytes to sites of infection [157].
The key role of IL-1β in this regard was exemplified by Miller and coworkers demonstrating
that neutrophil-mediated eradication of cutaneous S. aureus infection critically depended on IL-1
signaling [158].
Besides the beneficial role of IL-1β for clearance of infections, this cytokine has also been attributed
to contribute to the severity of inflammatory diseases [124,159]. For example, elevated IL-1 signaling
was demonstrated to cause neuronal cell death [160]. Of note, inflammasome activation and hence
elevated IL-1β production has been observed in patients suffering from epilepsy [161], stroke [162],
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Alzheimer’s disease [163], and other neurological disorders [164]. IL-1 is also an important mediator
of autoimmune diseases as evidenced by the therapeutic efficacy of IL-1Ra or IL-1β specific antibodies
for treatment of rheumatoid arthritis [159] and gouty arthritis [165]. Autoreactive T cells are a central
component of autoimmune diseases [166], and (myeloid) cells that generate IL-1 contribute to disease
progression [167]. In contrast, so-called autoinflammatory diseases are largely caused by dysregulated
IL-1β production [1]. As described above, hereditary gain-of-mutations in inflammasome components
are causative for diseases such as CAPS (see Section 2.2.1) that are also treated by IL-1 signaling
inhibition. Overproduction of IL-1β has also been observed in case of type 2 diabetes. Glucose itself
induced NF-κB activity and hence IL-1β expression in β cells [168]. Furthermore, minimally oxidized
low density lipoproteins were found to be elevated in diabetic patients which triggered IL-1β gene
expression via TLR4 engagement [169]. In the same study, accumulation of islet amyloid polypeptide
was shown to mediate NLRP3 inflammasome activation in islet macrophages [170]. In general, IL-1β
mediated destruction of pancreatic β islet cells which was counteracted in patients by administration
of IL-1Ra [171].
5. Role of IL-1β in Tumor Development
Proinflammatory innate cytokines including IL-1, TNF-α, and IL-6 are crucial to resolve acute
inflammations. However, high levels of innate cytokines as apparent in chronic inflammation
may promote tumor development by driving sustained NF-κB activation [172] and mitogen
activated protein kinase (MAPK) activity [173]. Moreover, these cytokines promote expression of
pro-tumorigenic genes that encode cell cycle, antiapoptotic and other proteins. Additional signaling
pathways including protein kinase B (AKT) or Wingless (WNT) have been attributed tumor-inducing
properties [174].
The development of multiple myeloma constitutes one example of a direct link between aberrant
IL-1 production and tumor induction. Multiple myeloma is characterized by an accumulation of
monoclonal plasma cells [175]. Smoldering multiple myeloma constitutes an early stage of multiple
myeloma as patients develop the disease within one to two years later [176]. The driving mechanism
is high level production of IL-1β by plasma cells which induces IL-6 in stromal cells [177]. IL-6 in turn
promotes the development of malign plasma cells. Treatment of patients expected to develop multiple
myeloma with IL-1Ra and the glucocorticoid dexamethasone proved successful to prevent further
disease progression [178].
5.1. Anti-Tumorigenic Effects of IL-1β
In agreement with the importance of IL-1 for the induction of type 1 and type 17 antigen-specific
T cell responses, the potential of recombinant IL-1 to induce pronounced anti-tumorigenic effects has
early been assessed. For example, Nakamura and coworkers [179] demonstrated that intratumoral
injection of IL-1a resulted in regression of different types of transplanted syngeneic tumors, including
sarcoma, melanoma, and adenocarcinoma. North and colleagues [180] observed tumor regression
only when IL-1 was applied intratumorally to tumors that had grown for a week, but not at earlier
timer points. Due to the finding that T cell-depleted mice showed no signs of IL-1 induced tumor
regression, the authors suggested that IL-1 was critical for the expansion of tumor antigen-specific
T cells. Besides these therapeutic effects, Allen and coworkers [181] demonstrated a protective role of
IL-1β in mouse models of chemically induced colitis and colon carcinoma. In myeloma-resistant
T cell receptor (TCR)-transgenic severe combined immunodeficiency (SCID) mice [182] injected
with myeloma cells, in vivo neutralization of IL-1 resulted in a decreased production of IFN-γ by
tumor-specific Th1 cells and attenuated infiltration of macrophages and tumor growth [183].
While application of recombinant IL-1 exerted anti-tumor effects in a number of mouse
studies (see above), in several clinical trials systemic application of IL-1 yielded only poor effects
on hematopoiesis and tumor development, but significant toxicity [184]. To prevent widespread
cytotoxicity, but to promote APC activation, IL-1 was encapsulated into microspheres [185]. These IL-1
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loaded microspheres were preferentially internalized by macrophages [186]. Intratumoral application
of such IL-1 delivery systems into fibrosarcoma-burdened mice delayed tumor growth which was
associated with tumor cell necrosis and strong infiltration of leukocytes.
Tumor cell necrosis resulting from pronounced type 1 [187] and type 17 [188] immune responses
and from chemotherapy [189] may further support the IL-1 signaling cascade by the release of
mitochondrial ATP [190]. Extracellular ATP binds the purinergic receptor P2RX7 and thereby stimulates
the NLRP3 inflammasome of myeloid APC [191]. Accordingly, mice deficient for NLRP3 inflammasome
activation and IL-1 and IL-17 signaling [192] showed no response to chemotherapy with immunogenic
cell death inducers such as anthracyclines. On cellular level, DC that lacked inflammasome activity
when incubated with dying tumor cells that released ATP as a NLRP3 inflammasome inducer were no
efficient CTL inducers [191]. Moreover, in anthracycline-treated breast cancer patients, an association
between the occurrence of an allele of the P2RX7 receptor with reduced binding affinity to ATP and
the beneficial effect of chemotherapy was observed. In contrast to these examples of anti-tumor effects
of IL-1β, a pro-tumorigenic role of this cytokine has been demonstrated in numerous studies, which is
outlined below.
5.2. Tumor-Promoting Effects of IL-1β
IL-1 plays a key role in carcinogenesis and tumor growth [193], due to its importance as a key
downstream mediator of inflammation [194]. Increased levels of IL-1β in body fluids are correlated in
experimental tumor models and in cancer patients with bad prognosis, carcinogenesis and invasiveness
of the tumor [195–197]. The key mechanisms by which IL-1β promotes tumor development are driving
chronic non-resolved inflammation [193], endothelial cell activation [194], tumor angiogenesis [195]
and induction of immunosuppressive cells (Figure 3). Altogether, these mechanisms account for
suppression of the adaptive immunity, tumor promotion and metastasis [193].
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Figure 3. Effects of IL-1 in the tumor microenvironment. IL-1 is expressed by tumor cells,
and predominantly by regulatory immune cell populations such as TAM and MDSC in the tumor
microenvironment. The interleukin exerts pro-tumorigenic autocrine and paracrine effects on several
levels in these cell types as well as in CAF which themselves do not generate IL-1 (blue arrows).
Protumorigenic effects of elevated IL-1 on these different cell types are counter-acted by administration
of IL-1Ra which competes with IL-1(α and β), and thereby prevents IL-1 signaling (red arrows).
In numerous studies, TAM and MDSC were demonstrated to specifically produce IL-1β. In accordance,
application of IL-1β specific antibodies intended to prevent induction of IL-1 signaling was shown to
confer anti-tumorigenic effects as well.
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5.2.1. Tumor Development Caused by Chronic Inflammation
By now, chronic inflammation is recognized as one of the hallmarks in carcinogenesis,
tumor progression, and metastasis [198,199]. Chronic inflammation results from the inability of the
body to resolve an acute inflammatory response. Persistent inflammation can trigger the development
of various tumors such as colorectal cancer, gastric cancer, mucosa-associated lymphoid tissue cancer,
lung cancer, bladder cancer, and HCC [200–202]. Hepatic inflammation for example as induced
by hepatitis C virus infection is a cytokine driven disease, especially via IL-1β, triggering the
transition from non-alcoholic fatty liver disease to severe fibrogenesis, and finally hepatocellular
carcinoma [203]. IL-1β is induced by a Helicobacter pylori infection, the most common chronic bacterial
infection, and is the etiological agent for gastric cancer [204]. The association of gastritis and gastric
tumor development has been shown to be strongly associated with genetic polymorphisms in the
IL-1β locus [205]. IL-1β therefore enhances the number of gastric tumors [206]. Another significant
mechanistic link between IL-1β and an increased risk of gastric cancer is the induction of aberrant
DNA methylation via this interleukin [207]. IL-1β is also about 2–3-fold upregulated in small airway
epithelial cells of chronic obstructive pulmonary disease (COPD) patients and seems to influence COPD
airway inflammation [202]. Because COPD is a known risk factor for developing lung cancer [208],
IL-1β seems to play a profound role in this regard as well. Additionally, the development and
invasiveness of tumors induced by the chemical carcinogen 3-methylcholanthrene (3MCA) is promoted
by IL-1β [209]. Furthermore, the induction of immunosuppressive myeloid-derived suppressor cells
(MDSC), regulatory T cells (Treg), tumor-associated macrophages (TAM) [210] and NK cells [211] is a
consequence of chronic inflammation. Altogether, IL-1β plays a major role already in the transition of
chronic inflammation to tumor induction.
5.2.2. Tumor Microenvironment
Immunosuppression
The tumor microenvironment is characterized by dominant immunosuppression. It is induced
by myeloid regulatory cells such as neutrophils [212,213], TAM [214–216], MDSC [217–220],
and regulatory DC [221,222]. In addition, Treg and carcinoma-associated fibroblasts (CAF) contribute
to the immunosuppressive milieu [222–225]. In a head and neck squamous cell carcinoma (HNSCC)
mouse model inflammasome activation and thereby IL-1β upregulation was shown to cause an
insufficient anti-tumor reactivity via the immunosuppressive network of MDSC, TAM and Treg [226].
MDSC and Treg have also been illustrated to be key negative regulators of the immune system in
melanoma patients [227–229].
TAM
Macrophages particularly populate the tumor microenvironment and are highly prevalent in
inflammation-mediated tumors. These cells are called alternatively activated (M2) macrophages [174,230].
In general, macrophages that infiltrate tumor tissues are driven by tumor-and T cell-derived
cytokines to acquire a polarized M2 phenotype characterized by production of IL-4, IL-13, IL-10,
and glucocorticoid hormones [227,231]. These mediators influence all aspects of tumor growth
and progression, providing a nurturing niche for cancer stem cells, and promoting angiogenesis,
e.g., by IL-1β, dependently expressed vascular endothelial growth factor (VEGF), paving the way for
metastasis, and taming adaptive immune response [193,216].
The sabotage of anti-tumor immunity is achieved by impairing T cell activation and by inhibiting
M1 macrophage-mediated innate anti-tumor immune responses [227]. TAM provide an inflammatory
microenvironment via inflammasome activation and IL-1β production which promotes, for example,
breast cancer progression [232]. IL-1β induces CCL2 expression in TAM and tumor cells as well,
regulating myeloid cell recruitment into tumor tissue [232,233].
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MDSC
MDSC are a heterogeneous population of immature myeloid cells that are precursors of DC,
macrophages, and granulocytes [234]. They are induced by tumor-derived soluble factors [235].
IL-1β is a tumor-associated factor leading to expansion and migration of MDSC, being regulated
by the IL-1RI/NF-κB pathway [236]. MDSC accumulate in the blood, lymph nodes, bone marrow
and at tumor sites in most patients and in tumor-burdened animals. These cells downregulate
immune surveillance and antitumor immunity by multiple mechanisms, thereby facilitating tumor
growth [227,234,237–243].
It could be shown that mice injected with 4T1 mammary carcinoma tumor cells transfected with
an IL-1β expression vector propagated significantly higher levels of MDSC compared to mice carrying
the same tumors but not secreting IL-1β [244]. Furthermore, the number of monocytic (mo-)MDSC
was significantly increased in the prematastatic lungs of tumor-bearing mice, thus promoting tumor
cell arrest on endothelial cells and metastasis [245]. The translational importance of IL-1β as a driver
of MDSC propagation is underlined by the finding that in peripheral blood of advanced melanoma
patients an increased level of serum IL-1β was associated with the frequency of mo-MDSC and
Treg. An enrichment of circulating mo-MDSC significantly correlated with decreased progression-free
survival of melanoma patients [246]. Furthermore, IL-1β upregulated cyclooxygenase-2 (COX-2),
which encodes prostaglandins that mediate MDSC propagation [247]. MDSC produce IL-1β and other
pro-inflammatory molecules activating tissue-resident endothelial cells to produce VEGF and other
angiogenic factors [248]. These proangiogenic factors induced endothelial cell proliferation and blood
vessel formation. Besides direct effects of IL-1β and products of its target genes on the expansion
of the MDSC pool, IL-1β induced CC-chemokine ligand 2 (CCL2) in macrophages and tumor cells.
Elevated CCL2 within the tumor microenvironment promoted the recruitment of C-C chemokine
receptor type 2 expressing (CCR2+) myeloid cell types, including MDSC and TAM [232].
Furthermore, IL-1β promotes cancer cell adhesion and hepatic metastases by up-regulation of
vascular cell adhesion molecule (VCAM-1) on hepatic sinusoidal endothelium [249,250]. It was also
revealed, that IL-1β expression in lungs of melanoma-bearing mice is facilitated by lung-recruited
mo-MDSC, resulting in enhanced E-selectin expression [245].
CAF
Another key player within the tumor microenvironment is the group of carcinoma-associated
fibroblasts (CAF) which contribute to the growth, expansion, and dissemination of cancer cells [251].
CAF originate from the activation of resident fibroblasts or a wide spectrum of other precursor
cells such as smooth muscle cells, bone marrow-derived mesenchymal stem cells, epithelial cells,
carcinoma cells, and many more [252,253]. CAF activation is triggered by a variety of stimuli,
including cancer cell-derived TGF-β1 (tumor growth factor-β1), PDGF (platelet-derived growth
factor)α, PDGFβ, basic fibroblast growth factor (bFGF), and IL-6 [254]. CAF contribute to the
malignant aggressiveness of tumors through the induction of pro-inflammatory factors including IL-1β,
IL-6/8, CCL2, CXCL (C-X-C motif ligand) 1/2/3/12, COX-2, osteopontin (OPN), and intercellular
adhesion molecule 1 (ICAM-1) [225,251]. IL-1β was also identified as a stromal-acting chemokine
secreted by ovarian cancer cells, suppressing p53 protein expression in CAF. p53 is known to
maintain genomic integrity through apoptosis regulation despite DNA damage or instability and also
regulates inflammation [255]. Knockdown of p53 expression significantly enhanced the expression and
secretion of chemokines IL-1β, IL-6, IL-8, growth regulated oncogene-alpha (GRO-α), and VEGF.
In vivo, a significant increase in mouse xenograft ovarian cancer tumor was seen as well [256].
Thereby, epithelial cancer cells use IL-1β as a communication factor to generate a pro-tumorigenic
inflammatory microenvironment [256]. Liver metastasis of colorectal cancer is promoted by recruiting
circulating CAF to facilitate prophase tumor construction tumorigenicity via an elevated expression
of structural maintenance of chromosomes 1A (SMC1A), a subunit of cohesin [257]. Furthermore,
it was demonstrated that signaling mediated by the G protein estrogen receptor (GPER) cells,
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induced by estrogen, triggered IL-1β and IL-1R1 expression in CAF and in breast cancer cells.
Thus, the ligand-activated GPER triggers the Epidermal Growth Factor Receptor (EGFR)/extracellular
signal–regulated kinases(ERK)/PKC signaling transduction pathway generating a feed forward loop
that couples IL-1β induction by CAF to IL-1R1 expression by cancer cells [258]. This resulted in
an up-regulation of IL-1β/IL1R1 target genes such as PTGES (prostaglandin E synthase), COX2,
RAGE (receptor for advanced glycation endproducts), and ABCG2 (ATP binding cassette subfamily
G member 2). Thereby, regulatory interaction between CAF and the cancer cells induces migration
and invasive features in breast cancer cells via alterations of fibroblastoid cytoarchitecture and F-actin
reorganization [258].
5.2.3. Angiogenesis
IL-1β promotes tumor development as well by influencing angiogenesis. Tumor growth requires
the sprouting of new capillaries from preexisting blood vessel. Microscopic in situ lesions of a tumor
may exist for years without having their own microcirculation. For tumor progression, an angiogenic
switch permits rapid growth and invasion [259,260]. It was shown that microenvironmental IL-1β
leads to in vivo angiogenesis and invasiveness of different tumor cells [260]. Confirming these results,
IL-1β secreting tumors showed enhanced tumor angiogenesis as evidenced by highly increased
secretion of VEGF by malignant cells and blood vessel density in tumors [222,261,262]. In the early
angiogenic response during tumor development, cross talk between VEGF and IL-1β takes place.
IL-1β and VEGF seem to induce each other and are both essential for blood vessel growth. Furthermore,
IL-1β induced CCL2 expression in macrophages and tumor cells [232]. CCL2 has been shown to have
multiple pro-tumorigenic functions such as mediating tumor growth and angiogenesis [233].
5.2.4. Metastasis
IL-1β paves the way for tumor induction and growth as well as metastasis. Tumor metastasis
is a complex process, including: (i) tumor cell dissemination from primary foci; (ii) their infiltration
into the vascular system; (iii) transition through the circulation; (iv) capture in capillary beds; and (v)
formation of metastatic nodules in distant target organs [263]. In the process of tumor metastasis,
the construction of a pre-metastatic microenvironment is an essential step. The environment of the
distant metastatic target organs are rebuilt prior to the arrival of the tumor cells from the primary
foci [264]. It could be shown that the number of mo-MDSC is significantly increased in the lungs of
melanoma-burdened mice before the arrival of tumor cells. These MDSC secreted IL-1β, resulting
in the expression of E-selectin in endothelia cells, being attributed to increased distant metastasis in
the lung [245]. Primary tumor cells enable a distant engraftment by secretion of different growth
factors [265], resulting in chemokine and cytokine upregulation in the metastatic targeted organ.
In primary and metastatic tumor tissue, elevated levels of IL-1β could be found [232]. Furthermore,
an augmentation of lung metastasis from A375M tumor cells could be observed after (IV) injection
of IL-1β [266]. Upregulated expression of proinflammatory chemokines and cytokines resulted in
recruitment of bone marrow-derived hematopoietic cells [267]. Mo-MDSC are a significant component
of these recruited cells [245].
In experimental studies, NLRP3 and thereby IL-1β expression levels were correlated with
the tumor size and the metastatic status of the sentinel lymph node [268]. IL-1β levels were also
shown to correlate with implantation and liver metastatic growth in a melanoma model [269,270].
Intravenous application of IL-1β enhanced the hepatic metastasizing ability of intrasplenically injected
B16 melanoma cells [270]. IL-1β and TNFα induced IL-18 release upregulating the expression of
VCAM-1 on hepatic sinusoidal endothelium (HSE) and thereby promoting cancer cell adhesion
and liver metastases [249]. An IL-1β dependent upregulation of VCAM-1 by HSE, accompanied
by elevated expression of the very late antigen-4 (VLA-4) could also be confirmed in another study.
Hereby, adhesion of the melanoma cells to HSE cells take place leading to an increased metastasis [271].
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6. Anti-Cancer Agents Induce IL-1β
Chemotherapy causes numerous undesirable symptoms affecting physical functioning and quality
of life. An association between cancer treatment-related symptoms and inflammatory cytokines could
be shown, triggered by increased production and synergistic action of IL-1β and TNFα [272,273].
IL-1β processing and secretion is induced by numerous chemotherapeutic drugs and has been shown
to either elevate IL-1β gene expression or inflammasome activity in myeloid cells (summarized in
Table 1).
Most recently, we have identified the clinically used B-Raf proto-oncogene, serine/threonine
kinase (BRAF)V600E inhibitors (BRAFi) Dabrafenib (DAB) and Vemurafenib (VEM) to simultaneously
mediate elevated IL-1β gene expression and inflammasome activation in DC and macrophages as an
off target effect [6]. BRAFi are used for the treatment of metastatic melanoma in cases of a mutation in
the signaling adaptor BRAF that results in ERK hyperactivation as an oncogenic target. This mutation
(BRAFV600E) can be found in about 40% of all melanomas. We observed that DAB strongly upregulated
IL-1β production in unstimulated and LPS-stimulated myeloid mouse APC and in unstimulated
human primary DC. VEM also enhanced IL-1β secretion by mouse DC and macrophages, but not in
human DC. Both BRAFi activated the NLRC4 inflammasome, and DAB additionally induced caspase-8
activation for pro-IL-1β processing. Contrarily, the newly developed BRAFi Encorafenib (ENC) had no
effect on IL-1β production (Figure 4). The recently conducted phase III study for applying ENC plus the
accordingly applied MEK1/2 inhibitor Binimetinib versus VEM or ENC administered alone showed
improved progression-free survival and improved overall response of Encorafenib/Binimetinib treated
patients. Treatment with ENC exerted less adverse events such as rash compared to VEM, although
the frequency of grade 3 rash was slightly increased [274].
In our study on the IL-1β promoting effects of BRAFi, in the case of human primary DC isolated
from peripheral blood, only a fraction of samples responded to DAB treatment with an induction of
IL-1β [254]. These results are in line with the clinically observed side effect of DAB to cause fever in
about 40–50% of patients treated with that BRAFi [275] which could be mediated by induced IL-1β due
to its pronounced pyrogenic effects. Thus, these results suggest that genetic polymorphisms within the
IL-1β or inflammasome genes determine the occurrence of these immunmodulatory off target effects
of DAB.
The observation that chemotherapeutics may increase IL-1β levels in tumor patients may be
detrimental for tumor therapy and therefore needs to be taken into consideration. Westborn et al.
showed that treatment of SCID mice and Hmeso cells with the IL-1β inducing chemotherapeutic
doxorubicin in combination with IL-1Ra resulted in a smaller tumor size compared to single cisplatin
or IL-1Ra treatment [276]. Applying IL-1Ra in combination with cytotoxic chemotherapy seems such
as a potential targeting option to reduce IL-1β dependent side effect of chemotherapeutic treatment.
Furthermore, BRAFi treatment-induced tolerance in melanoma could be shown to result from a
cytokine-signaling network involving TAM-derived IL-1β and CAFs derived C-X-C motif chemokine
receptor 2 (CXCR2) ligands. The loss of host IL-1R signaling reduced melanoma growth in vivo as
well [277]. These results could be confirmed in another study issuing the outcome of breast and
lung carcinoma treatment with paclitaxel in combination with Anakinra. This combination treatment
resulted in a reduced tumor burden. However, the combined therapy increased metastasis in mice
lungs when compared to a monotherapy with paclitaxel. Thus, dual effects of blocking the IL1 pathway
on tumor growth are possible. Therefore, treatments using “add-on” drugs such as the IL-1β blocker
to conventional chemotherapy should be investigated in appropriate tumor models monitoring both
the primary tumor and the induction of metastases [278].
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Figure 4. Effects of BRAF inhibitors on IL-1β production by DC. Murine bone marrow-derived DC at
(A) unstimulated state or (B) treated with LPS [100 ng/mL] were (co)administered with varying doses
of BRAF inhibitors. DAB, but not ENC induced IL-1β production in DC at either state of activation
(mean ± SD; n = 4).
7. Inhibition of IL-1 Signaling Inhibits Tumor Growth
7.1. Genetic Models
Chronic high-level expression of bioactive IL-1β is an important promotor of tumor
development [209]. IL-1β is involved in the positive feedback loop of IL-1β/Akt/retinoic acid receptor
α (RARα) signaling, and thereby transmits the oncogenic property of RARα in gastric carcinoma [279].
In transgenic mice the expression of human IL-1β induced spontaneous gastric cancer, correlating with
early recruitment of MDSC to the stomach [236]. H. pylori infection was also shown to induce IL-1β
production which played a crucial role in gastric inflammation. IL-1R1 deficient mice demonstrated
attenuated infiltration of inflammatory cells, especially of macrophages and neutrophils, into the
stomach of H. pylori infected animals compared with wild type (WT) mice [280]. Furthermore, reduced
susceptibility to gastric carcinogenesis could be observed in IL-1R1-/- mice. Similarly, IL-1β-/- mice
were characterized by a reduction of H. pylori induced gastric tumors [206].
IL-1β was reported to induce methylation-dependent gene silencing via nitric oxide (NO)
production [280]. NO-induced aberrant DNA methylation is one of the major inactivating mechanisms
of tumor suppressor genes. An absence of E-cadherin promotor methylation in IL-1R1-/- mice was
observed, therefore IL-1 induced methylation is likely to be one of the major mechanisms for chronic
inflammation inducing cancer [206,280]. Therefore, gastric inflammation is considered as an inducer
of DNA methylation and as a driving force in gastric carcinogenesis.
Additionally, IL-1β driven chronic Inflammation promoted the development and invasiveness
of chemical carcinogen-induced tumors as well [196,260]. Mice deficient for IL-1β or IL-1R1 were
protected against methylcholanthrene (MCA) carcinogenesis. At the site of carcinogen injection,
a sparse leukocyte infiltration occurred in IL-1β deficient mice opposing the dense neutrophile
infiltration in IL-1Ra-/- mice. In WT and IL-1α-/- mice leukocyte infiltration at this site was apparent
being dominated by macrophages, whereas in the IL-1β-/- mice cellular infiltration was nearly
absent [209].
Another important aspect of tumor growth being modulated and influenced by IL-1β knockout
is the development of metastasis. In a breast cancer model, mice deficient for caspase-1 and thereby
having reduced IL-1β levels exhibited significantly lower numbers of lung metastasis and attenuated
tumor growth [232]. In a human oral squamous cell carcinoma (OSCC) model NLRP3 expression levels
correlated with tumor size, lymph node metastatic status and IL-1β expression. Down-regulation
of NLRP3 expression using short hairpin RNA markedly reduced IL-1β production and OSCC cell
proliferation, migration and invasion. Moreover, silencing NLRP3 expression significantly inhibited
OSCC tumor growth in vivo [268].
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Table 1. Anti-tumor drugs that induce IL-1β.
Anti-Tumor
Agent Doses
IL-1β Enhancement Via Effects IL-1β Production
Incubation Cell Type DetectionMethod RefGene
Expression
Inflamma-
Some ? Synergistic Additive Amounts
Pro-
IL-1β IL-1β
Dabrafenib 0.1; 1; 2.5; 5 µM x NLRC4 - - MTX ~10 ng/mL 24 h hDC, mBMDM, splenicmye. cell pop qPCR, FACS [6]
Vemurafenib 0.1; 1; 2.5; 5 µM - NLRC5 - - - ~1 ng/mL 24 h mBMDM, splenic DC qPCR, FACS [6]
Doxorubicin
2.5; 10; 25; 100 µM - NLRP3 - - - max. 700 pg (10 µM) 8 h mBMDM ELISA [281]
5 µM - NLRP3 - - - ↑↑↑ 18 h mBMDM WB [273]
5 µM - - x - - ~45 fold x 2, 12, 24 h mBMDM, mouse blood FACS, qPCR [282]
10 µM - NLRP3 - - - 6.5 pg/mL IL-1β 48 h Hmeso/H2373 MM cells ELISA/WB [276]
5 µM - NLRP3 - - - ~2300 pg/mL IL-1β x 2, 2–18 h mBMDC ELISA/WB [283]
Daunorubicin 0.1; 0.25; 1; 2.5 µM - NLRP3 - - - 230 pg/mL 8 h mBMDM ELISA [281]
Melphalan 2.8 µM - NLRP3 - - - ↑↑↑ 18 h mBMDM WB [273]
Cisplatin
17 µM - NLRP3 - - - ↑↑ 18 h mBMDM WB [273]
100 µM - NLRP3 - - - 2.5 pg/mL IL-1β 48 h Hmeso/H2373MM cells ELISA/WB [276]
50 µM - NLRP3 - - - 13.2 nmol/mg/min ? proximal tubulus cells ELISA [284]
20 mg/kgKG I.p - x - - ~13 pg/mg 72 h mouse kidney tissue ELISA [285]
Vincrisitin 0.4 µM - NLRP3 - - - ↑↑ 18 h mBMDM WB [273]
Etoposide 33 µM - NLRP3 - - - ↑↑ 18 h mBMDM WB [273]
Paclitaxel
1 µM - NLRP3 - - - ↑ 18 h mBMDM WB [273]
200 nM/L
25/50 mg/kgKG - x - - ~0.35 pg/mL x
24 h,
6, 12, 24, 48 h blood
ELISA,
RT-PCR [278]
2 mg/kg - NLRP3 - - - ~220%. x 1/2/3 weeks macrophages RT-PCR [286]
4 mg/kg - x - - ~1.7 fold x 36 days dorsal root ganglia RT-PCR [287]
Methotrexate 2.3 µM - NLRP3 - - - ↑ 18 h mBMDM WB [273]
Cytarabine 2 µM - NLRP3 - - - ↑ 18 h mBMDM WB [273]
5-Flu 1 µM - NLRP3 - - - ~60 pg/mL 24, 48, 72 h mMDSC ELISA [288]
Gemcitabine 27 nM - NLRP3 - - - ~70 pg/mL 24, 48, 72 h mMDSC ELISA [288]
Doxo. & Vincr 5 µM & 0.4 µM - NLRP3 - + - ↑↑↑ 18 h mBMDM WB [273]
Cispl. & Vincr 17 µM & 0.4 µM - NLRP3 - - + ↑↑ 18 h mBMDM WB [273]
WB, Western Blot; h, human; m, mouse; BMDM, bone morrow-derived macrophage; myel., myeloid; ?, unknown; ↑/↑↑/↑↑↑, light/ medium/high upregulation of IL-1β.
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7.2. Pharmacological Inhibition
As outlined above, inhibition of IL-1β signaling by using appropriate mouse models was shown
to influence multiple key mechanisms of tumor growth such as chronic inflammation that triggered
tumor development [193], accumulation of immunosuppressive cells in the tumor milieu [194],
angiogenesis [195] within the tumor microenvironment, and metastasis [196]. Therefore, blockade of
IL-1β may constitute an important therapeutic rationale to impair tumor development and progression.
Moreover, it may serve to reduce therapeutic side effects and for palliative care [289].
Several types of agents are available to prevent the biological activtiy of IL-1β, including
IL-1β specific antibodies (Canakinumab) [290] and IL1Ra (Anakinra) [290] as well as inflammasome
inhibitors (Thalidomide, Parthenolide, and BAY-11-7082) [260,289,291]. The two IL-1 blocking agents
Anakinra and Canakinumab have already been approved for the treatment of systemic inflammatory
disorders and display an excellent safety profile [290].
7.3. Immuno-Suppression
In the tumor microenvironment in HNSCC, impairment of T cell responses resulted in an
immunosuppressive state which is caused by MDSC, Treg and TAM [292,293]. TAM and MDSC can be
recruited to the tumor side by IL-1β [232]. In agreement, in a mouse breast cancer model inhibition of
NLRP3 effectively reduced the tumor-resident population of MDCS [288] and TAM [232]. Similarly,
in a HNSCC mouse model, a reduction of MDSC, Treg and TAM frequencies was achieved by blocking
NLRP3 inflammasome activation using the specific inhibitor MCC950 [226]. Comparable effects were
observed in murine and human breast cancer models when applying Anakinra. In these studies,
blockade of IL-1 signaling was accompanied by a lower myeloid cell accumulation in the tumor
microenvironment whereas normal inflammasome activity contrarily lead to the infiltration of MDSC
and TAM into the microenvironment [232]. Furthermore, it could be shown, using the mouse mammary
tumor virus (MMTV)—inducible fibroblast growth factor receptor 1 (iFGFR1) transgenic mouse model,
that inhibition of IL-1β activity in vivo resulted in reduced iFGFR1 induced mammary epithelial
proliferation and attenuated formation of hyperplasic structures. Targeting IL-1β partially inhibited
formation of early-stage mammary lesions in part through the induction of Cox2 [294].
7.4. Angiogenesis
Without appropriate vascularization tumor cells become necrotic and/or apoptotic. In several
studies, angiogenesis was assessed by the recruitment of blood vessel networks into Matrigel plugs
containing tumor cells that were inoculated s.c. in mice. In case of IL-1β-/- mice, no vascularization
of Matrigel plugs containing B16 melanoma cells occurred. Moreover, the incorporation of IL-1Ra to
B16 containing plugs in WT mice inhibited the ingrowth of blood vessel networks into the plugs as
well [260]. The necessity of IL-1β for angiogenesis and invasiveness of the tumor in vivo was also
verified in DA/3 mammary and prostate cancer cell models [260].
VEGF and IL-1β were demonstrated to interact in an autocrine circuit using Matrigel plugs
supplemented with B16 melanoma cells. IL-1β inhibition reduced tumor growth for an extended
period. In contrast, specific VEGF neutralization initially resulted in an initial tumor inhibition,
but followed by tumor recurrence [4]. Additionally, IL-1β was induced by leptin, leading to an increase
in the expression of VEGF/VEGFR-2. Moreover, leptin upregulation of VEGF/VEGFR2 was partially
mediated by IL-1 signaling [295]. This triad of cross talk among IL-1, VEGF, and leptin promoted
angiogenesis in breast tumors. This interaction is an important driver of leptin-induced oncogenic
action and a key link between obesity and cancer progression [296]. It could also be shown that
NLRP3-dependent IL-1β promoted lymphangiogenesis by human macrophages via a S1P receptor
1(S1Pr1)-dependent pathway in vitro. The strong reduction of IL-1β in S1PR1 deficient TAM prevented
lymphangiogenesis [297].
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7.5. Metastasis
In a murine B16 melanoma metastasis model, intrasplenic injection of recombinant IL-1β or LPS
increased experimental liver metastasis, while reduction of metastases and increased survival rates
were observed following IL-1Ra treatment [269,270]. A similar outcome was confirmed in numerous
studies in which exogenous IL-1Ra exerted an inhibitory effect of on lung and liver experimental
metastasis of human and murine melanoma cells [249,250,291].
The results of the aforementioned studies led to the conclusion that inhibition of IL-1 signaling
has a pronounced inhibitory effect on tumor growth by targeting different mechanisms of tumor
development, such as: (i) reducing chronic inflammation which triggers tumor development;
(ii) propagation of immune-suppressive cells; (iii) accumulation of regulatory cells in the tumor
milieu; (iv) angiogenesis; and (v) metastasis.
8. Concluding Remarks
In the last decades, research has gathered a wealth of information on parameters that regulate
IL-1β expression and on the multi-facetted role of IL-1β in pathophysiological conditions. IL-1β
promotes APC-stimulatory activity and the upregulation of adhesion receptors on immune and
endothelial cells as a prerequisite for the infiltration of leukocytes to sites of infection in acute
inflammation. As a consequence of gain-of-function mutations of IL-1 expression regulating
components, IL-1β is a driver of autoinflammatory diseases.
However, conflicting effects of IL-1β in terms of tumor development have been observed.
Due to the induction of type 1 and type 17 antigen-specific T cell responses IL-1β exerts
anti-tumorigenic effects. Contrarily, IL-1β within the tumor microenvironment can promote
carcinogenesis, tumor growth, and metastasis by different key mechanisms such as driving chronic
non-resolved inflammation, endothelial cell activation, tumor angiogenesis, and the induction of
immune-suppressive cells. Clinically, a correlation between high levels of IL-1β and bad prognosis
in cancer patients was observed. Therefore, numerous studies on IL-1β and its inhibition in animal
and human tumor models were conducted. IL-1 signaling (Anakinra), and more specifically IL-1β
(antibody-mediated) inhibition hereby seem to target key components of tumor development in most
cases resulting in reduced tumor development.
Several drugs used for cancer treatment were shown to induce IL-1β production, which may
lead to unwanted side effects. A combination of these drugs with IL-1Ra or an IL-1β blocking
antibody reduced side effects and smaller tumor growth. Another study, however, showed that
chemotherapeutic treatment with an additional IL-1β inhibitor also reduced tumor growth,
but increased metastasis. Therefore, treatments using “add-on” drugs that inhibit IL-1 signaling
in combination with conventional therapy should be investigated in appropriate tumor models looking
at the primary tumor site as well as metastasis.
Overall, latest data suggest that (additional) IL-1β inhibition in numerous tumor models is a
promising therapeutic option. Further consistent research in experimental mouse models is needed to
assess the efficacy of IL-1β blockade in combination with chemotherapeutics or other drug treatment
such as immunotherapy. Although growing evidence confirms beneficial effects of IL-1 signaling
inhibition in tumor therapy, surprisingly, it is not standard treatment yet, even though the FDA
approved IL-1 blockers such as Anakinra and Canakinumab for treatment of systemic inflammatory
disorders and both drugs show an excellent safety profile.
To potentially enhance the overall efficacy of anti-tumor drugs known to induce IL-1β, the efficacy
of additional IL-1 signaling blockade needs to be evaluated in tumor therapy.
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Abbreviations
APC Antigen presenting cell
BMDC Bone morrow-derived macrophages
BRAFi BRAF Inhibitor
CAF Carcinoma-associated fibroblasts
DAB Dabrafenib
DC Dentritic cell
ENC Encorafenib
HNSCC Head and neck squamous cell carcinoma
IL-1α Interleukin-1 alpha
IL-1β Interleukin-1 beta
IL-1Ra Interleukin-1 receptor
LPS Lipopolysaccharide
MCA Methylcholanthrene
MyD88 Myeloid differentiation primary response 88
MDSC Myeloid-derived suppressor cells
NK Natural killer cells
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B-cells
TAM Tumor-associated macrophages
Th T helper type T
TLR Toll-like receptor
Treg Regulatory T cells
VEGF Vascular Endothelial Growth Factor
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